

GUEST SPEAKERS



Bisola Ojikutu, MD, Brigham and Women's Hospital

Bisola Ojikutu is an infectious disease physician who has dedicated her career to overcoming racial and ethnic inequity experienced by people living with or at risk for HIV. Dr. Ojikutu is an Assistant Professor of Medicine and Global and Social Medicine at Harvard Medical School and an Associate Physician within the Division of Global Health Equity at Brigham and Women's Hospital. She is also a faculty member within the Infectious Disease Divisions at Brigham and Women's and Massachusetts General Hospitals. Her research explores the impact of structural factors and norms/beliefs (e.g. racism/discrimination, immigration, medical mistrust, homonegativity) on HIV transmission and use of biomedical HIV prevention.

Much of her work has focused on collaborative engagement of marginalized communities in research. To that end, she is the Director of the Community Engaged Research Program and the Associate Director of the Bio-Behavioral and Community Science Core within the Harvard University Center for AIDS Research. Dr. Ojikutu is co-editor of two comprehensive textbooks detailing the HIV epidemic with Black and Latinx communities, *HIV in US Communities of Color* (first and second editions 2009 and 2020) and has lectured widely on the topic. She is also a leader within the Massachusetts statewide Getting to Zero and Ending the HIV Epidemic Steering Committees. Internationally, Dr. Ojikutu has worked throughout sub Saharan Africa developing and evaluating models of care for people living with HIV. As a Senior Advisor at John Snow Research and Training Institute, she has led USAID-funded HIV service implementation projects focused on expansion of HIV treatment. At HMS, she is co-Principal Investigator of the Doris Duke International Clinical Research Fellowship for Medical Students and is the former Director of the Office of International Programs within the Division of AIDS at Harvard Medical School.

Dr. Ojikutu graduated from Johns Hopkins School of Medicine, completed residency in Primary Care-Internal Medicine at New York Presbyterian Hospital, and Infectious Disease Fellowship at Massachusetts General Hospital/Brigham and Women's Hospital. She received a Master of Public Health from Harvard School of Public Health and was a Commonwealth Fund/Mongan Fellow in Minority Health Policy at Harvard University. For the past 15 years Dr. Ojikutu has maintained an active clinical practice focusing on the treatment of HIV, primary care and general infectious diseases.

Source: <https://www.lgbthealtheducation.org/us/faculty-advisory-board/bisola-ojikutu/>



Katy Stephenson, MD, Beth Israel Deaconess Medical Center

Dr. Stephenson is a physician-scientist who specializes in infectious diseases and HIV immunology, and the goal of her research is to develop novel biomedical interventions to prevent and treat HIV and emerging infectious diseases such as Zika virus. In particular, she is interested in the design and evaluation of HIV vaccines and monoclonal antibodies that can be effective in the face of tremendous HIV sequence diversity, as well as in the development of Zika vaccines. As an immunologist, her expertise is in the extensive epitope mapping of cellular and humoral immune responses. As a clinical investigator, her expertise is in the translation of novel vaccines and monoclonal antibodies into First-in-Human, Phase 1 clinical trials, and she is the Director of the Center for Virology and Vaccine Research Clinical Trials Unit. She is also Associate Editor of *Clinical Immunology*.

Source: <https://cvr.hms.harvard.edu/lab-member/kathryn-e-stephenson-m-d-m-p-h/>



Nina Lin, MD, Boston Medical Center

Dr. Nina Lin is a physician scientist who is engaged in HIV translational research. Her research is focused on understanding factors and risks contributing to chronic inflammation in HIV infections and maintenance of HIV reservoir. She is the PI on several clinical trials, including co-Chair of ACTG A5325/A5220s and several NIH-sponsored independent clinical studies. She is the Director of the BU Infectious Disease Clinical Research Unit (CRU) where several HIV and/or infectious diseases clinical studies are being conducted, and recently at BMC have led several COVID-19 treatment trials, and a member of the COVID research committee. She is a co-director of the Brown-BUSM Biobehavioral Core and provides clinical research assistance across institutions. She continues to care for HIV infected patients in ID outpatient continuity clinic and attends in the inpatient ID service at BMC.

Source: <https://profiles.bu.edu/Nina.Lin>



Karen Tashima, MD, Miriam Hospital

Karen T. Tashima is a Professor of Medicine, Infectious Disease clinician, and clinical research scientist at Warren Alpert Medical School of Brown University. She also serves as Scientific Director of HIV Care at The Miriam Hospital and Chair of The Miriam Hospital Institutional Review Board. Dr. Tashima's primary research focuses on interventions for HIV, HCV, and other infectious diseases. She has directed a clinical trials unit for the last 20 years to investigate and improve upon aspects of HIV care including antiretroviral medications, comorbidities, adverse drug effects, therapeutic vaccines, HIV drug resistance, and co-infection with hepatitis C. Currently, the focus of studies includes testing cure strategies, novel delivery of antiretroviral medications, and residual inflammation associated with well-controlled HIV infection. Dr. Tashima's clinical studies address the needs of the local Rhode Island population and facilitate participation of women, minorities, persons with substance use disorders, and those with adherence challenges.

Dr. Tashima is co-chair of a national [AIDS Clinical Trials Group](#) study to test long acting antiretroviral medications administered as monthly injections in patients who have difficulty adhering to oral daily medications. The study is collaborative with other disciplines, including social work, case management, mental health, and is patient-centered while investigating the benefits of a long acting antiretroviral treatment. She mentors trainees and junior faculty in the design and conduct of clinical trials. Dr. Tashima oversees research in the division, mentoring junior faculty, and providing research staff support. She oversees the CFAR RISE laboratory, with two laboratory technicians processing, shipping and storing all types of research specimens. Dr. Tashima is also involved in inpatient infectious disease studies including novel *Clostridioides difficile* treatments in an ongoing collaboration with Dr. Colleen Kelly, GI Division, and strategies for treatment of complicated urinary tract infections (<https://www.niaid.nih.gov/research/antibacterial-resistance-leadership-group>). Dr. Tashima also works closely with [Omar Galarraga, PhD](#), who is a health economics researcher at Brown and is a team member on the long acting ACTG HIV treatment study.

Source: <http://brownmedicine.org/3/infectious-diseases-tashima/>



Adrianna Boulin, MPH, Fenway Institute

Adrianna Boulin is the Community Outreach & Engagement Manager at the Fenway Institute. Adrianna is a natural problem solver and believes that through proper planning, research and keen observation of the specific communities that we are trying to help that we will bring about their success. She has applied this belief in her initiatives to include the settings of Jamaica, South Africa, eSwatini (Swaziland) and Kenya. Her efforts have been recognized by both academic institutions, social enterprises and other non-profit entities. Adrianna holds a Bachelor of Science degree in Biology, with certificates in Italian and Eastern Mediterranean Security Studies from Emmanuel College in Boston and a Master of Public Health in Urban Health from Northeastern University in Boston.

Source: <https://www.linkedin.com/in/adrianna-boulin-4b653755/>



Paul Goulet, Chair of the ProvBos CFAR-Community Engaged Research Council (C-CERC)

With more than 28 years of experience working in health policy and consumer advocacy, my passion is to coordinate and implement efforts to expand health care access, improve quality and build community participation in health policy and health care systems. Most recently, I served as the Program Manager for the Special Linkage and Retention Team (ARCH Team) at the Shapiro Clinic, Center for Infectious Disease, Boston Medical Center.

As the former Director of the Consumer Office and Coordinator of Community Engagement at the Massachusetts Department of Public Health for over fifteen years and the former facilitator of the Statewide Consumer Advisory Board, I am a professional with a track record of successful consumer and community engagement within Massachusetts and other states. I am a board member of the National Quality Center, Consumer Advisory Council, and the Chair of the New England Association of Gay and Bisexual Men's Health covering six New England States.

Source: <https://www.brown.edu/academics/medical/about-us/research/centers-institutes-and-programs/aids/people/paul-goulet-chair>

MODERATORS AND PANELISTS



Jonathan Li, MD, Brigham and Women's Hospital

Dr. Jonathan Li is an Assistant Professor of Medicine at Harvard Medical School and a faculty member in the Division of Infectious Diseases at the Brigham and Women's Hospital. He is the Director of the Harvard/Brigham Virology Specialty Laboratory, the Director of the Harvard University Center for AIDS Research Clinical Core and a member of the AIDS Clinical Trials Group Executive Committee. His research is focused on HIV and SARS-CoV-2 drug resistance, reservoirs, and viral remission. He is active in the AIDS Clinical Trials Group (ACTG) as a member of the ACTG HIV Reservoirs and Viral Eradication Transformative Science Group and as the Chair of several ACTG clinical trials.

He is the Deputy Editor of the IDSA journal Open Forum Infectious Diseases and on the Editorial Advisory Board of the Journal of Infectious Diseases. In addition, he sees patients in both the outpatient Infectious Diseases clinic and in the inpatient consult service at the Brigham and Women's Hospital.

Source: <https://jonathanlilab.bwh.harvard.edu/>



Susan Cu-Uvin, MD, Miriam Hospital

Dr. Susan Cu-Uvin is Professor of Obstetrics and Gynecology and Medicine at the Alpert School of Medicine, Brown University and Professor of Health Services, Policy and Practice at the School of Public Health. She is the Director of the Brown Global Health Initiative and Principal Investigator of a D43 HIV and Cervical CA Training Grant with MOI University in Kenya. She is the director of the Providence / Boston Center for AIDS Research (CFAR). She was the Director of the Immunology Center at the Miriam Hospital, Brown University, a clinic that now serves 1,700 HIV infected patients until mid 2009. She chaired the Women's Health Committee of the Adult AIDS Clinical Trials Group (ACTG) from 2003-2006. She had been NIH funded since 1996 and the Principal Investigator of several

RO1s to assess HIV dynamics in the female genital tract. She was a co-investigator of the CDC funded study to understand the natural history of HIV in women (HERS) and the study to understand the natural history of HIV and AIDS in the era of highly active antiretroviral therapy (SUN). She had a K24 Mid-Career Investigator Award in Patient Oriented Research which allowed her to mentor several junior investigators locally as well as internationally. She has been a co-investigator in studies related to mucosal immunity, microbicides, STI's and immune reconstitution in the female genital tract. She is a member of the Public Health Service Task Force/Perinatal Antiretroviral Guidelines Working Group, Office of AIDS Research Advisory Council and the NIH advisory committee on HIV related research in women and girls. She is a member of the NIH advisory committee on HIV related research in microbicides and chairs the HPV Working Group, USPHS/IDSA Guidelines for the Prevention and Treatment of Opportunistic Infections. She was the recipient of the Constance B. Wofsy Women's Health Investigator Award from the AIDS Clinical Trials Group. She is a member of the Adult / Adolescent HIV Guidelines and the CDC STD Treatment Guidelines.

Source: <https://vivo.brown.edu/display/suvinmd>



Sandy Burchett, MD, MSc, Boston Children's Hospital

Dr. Burchett is a Senior Associate Physician in Pediatrics, Division of Infectious Diseases; Director, Children's Hospital AIDS Program (CHAP) and Perinatal Diagnostic Clinic; Co-Director, Immunocompromised Host and Transplant Infectious Disease Services; Associate Professor of Pediatrics, Harvard Medical School. Dr. Burchett's long standing research participation has been in prevention and treatment of perinatally acquired HIV and other viral infections, and in treatment and behavioral health of children, youth and young adults with HIV infection with 30 years of clinical trials experience in PACTG (Pediatric AIDS Clinical Trials); IMPAACT (International Maternal Pediatric Adolescent AIDS Clinical Trials) and PHACS (Pediatric HIV/AIDS Cohort Study) groups.

Source: <https://www.childrenshospital.org/directory/physicians/b/sandra-burchett>



Boris Juelg, MD, PhD, Massachusetts General Hospital

Dr. Boris D. Juelg is an Assistant Professor of Medicine at Harvard Medical School and a physician in the Division of Infectious Diseases at Massachusetts General Hospital (MGH). He is an Associate Member of the Ragon Institute of MGH, MIT and Harvard.

As a physician-scientist, Dr. Juelg aims to link preclinical and clinical studies to identify and test the most promising immunological strategies to prevent and treat HIV infection. He is specifically interested in evaluating passive and active immunization approaches using broadly neutralizing antibodies and novel vaccine candidates. In close collaboration with other investigators at the Ragon Institute, Dr. Juelg is conducting phase I/II clinical trials that are testing such concepts and translating findings from the lab into the clinic.

Source: <https://www.ragoninstitute.org/portfolio-item/juelg/>



Douglas Krakower, MD, Beth Israel Deaconess Medical Center

Dr. Douglas Krakower is Faculty in the Division of Infectious Diseases at Beth Israel Deaconess Medical Center, Research Scientist at The Fenway Institute, and Assistant Professor in Medicine and Population Medicine at Harvard Medical School. His research focuses on ways to optimize HIV prevention in healthcare settings with a focus on implementing HIV pre-exposure prophylaxis (PrEP). He is current leading efforts to recruit adolescent men and transgender females for HPTN 083-01, study of the safety, acceptability, and tolerability of long-acting injectable PrEP at Fenway.

Source: <https://www.populationmedicine.org/dkrakower>